echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Focus on rare disease "red spot limb pain": FDA awards ATX01 orphan drug title

    Focus on rare disease "red spot limb pain": FDA awards ATX01 orphan drug title

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    European biotech company Algo Therapeutix announced today that the U.SFood and Drug Administration (FDA) has awarded ATX01 (Amitlin gel) orphan drug for the treatment of erythromemelalgiaErydy limb pain is a rare disease, a plant nervous system disease characterized by elevated skin temperature at the far end of the limb and severe burning painAlthough erythema is thought to be caused by abnormal vascular contraction or dysfunction, the pain of erythema pain is thought to be associated with sodium channel dysfunctionATX01 (Amitlin gel) is mainly targeted at peripheral neuropathy caused by chemotherapyBy applying proprietary high-concentration amitillin gels locally, ATX01 is designed to reach damaged nerve fibers directly in the skin and to avoid systemic side effects of oral and injectable compoundsPreclinical studies have shown that local amitlin has an ananalgesic effect on voltage gated sodium channels Nav1.7, Nav1.8 and Nav1.9, as well as peripheral sensory nerve fibers A beta, A- and CATX01 will enter Phase I clinical development in late 2020 to treat erythema
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.